Charles Berg Net Worth (2024) – wallmine.com (2025)

Last updated: 17 May 2024 at 5:33pm EST

The estimated Net Worth of Charles Berg is at least $16.6 Million dollars as of 9 March 2023. Mr. Berg owns over 1,431 units of DaVita Inc stock worth over $2,207,340 and over the last 17 years he sold DVA stock worth over $9,035,728. In addition, he makes $5,342,990 as Director at DaVita Inc.

Mr. Berg DVA stock SEC Form 4 insiders trading

Charles has made over 26 trades of the DaVita Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 1,431 units of DVA stock worth $107,511 on 9 March 2023.

The largest trade he's ever made was exercising 150,000 units of DaVita Inc stock on 27 February 2012 worth over $3,582,000. On average, Charles trades about 3,608 units every 29 days since 2007. As of 9 March 2023 he still owns at least 15,733 units of DaVita Inc stock.

You can see the complete history of Mr. Berg stock trades at the bottom of the page.

CharlesBerg biography

Charles G. Berg J.D. serves as Director of the Company. Mr. Berg has been one of our directors since March 2007, and from November 2016 until December 2017, also served as executive chair of our integrated healthcare business, DaVita Medical Group (“DMG”). On March 25, 2019, Mr. Berg joined the board of directors of Turn-Key Health, an Enclara Healthcare company, serving health plans, provider organizations and their members who experience a serious or advanced illness. From 2008 to 2013, Mr. Berg served as executive chairman of WellCare Health Plans, Inc. (“WellCare”), a provider of managed care services for government-sponsored healthcare programs. Mr. Berg served as non-executive chairman of the board of directors of WellCare from January 2011 until his retirement in May 2013. From January 2007 to April 2009, Mr. Berg was a senior advisor to Welsh, Carson, Anderson & Stowe, a private equity firm. From April 1998 to July 2004, Mr. Berg held various executive positions, including executive vice president-medical delivery, president and chief operating officer with Oxford Health Plans, Inc. (“Oxford”), a health benefit plan provider. He was the chief executive officer when Oxford was acquired by UnitedHealth Group. He then became an executive of UnitedHealth Group and was primarily responsible for integrating the Oxford business. Mr. Berg currently serves as a member of the Operating Council & Senior Advisory Board of Consonance Capital Partners, a private equity firm, and the board of directors of Justworks, Inc., a private human resources and payment company. Mr. Berg is an experienced business leader with significant experience in the healthcare industry and brings an understanding of the operational, financial and regulatory aspects of our industry and business.

What is the salary of Charles Berg?

As the Director of DaVita Inc, the total compensation of Charles Berg at DaVita Inc is $5,342,990. There are 2 executives at DaVita Inc getting paid more, with JavierRodriguez having the highest compensation of $16,853,500.

What's Charles Berg's mailing address?

Charles's mailing address filed with the SEC is C/O DAVITA INC., 2000 16TH STREET, DENVER, CO, 80202.

Insiders trading at DaVita Inc

Over the last 21 years, insiders at DaVita Inc have traded over $515,422,025 worth of DaVita Inc stock and bought 20,841,023 units worth $1,590,012,094. The most active insiders traders include Hathaway Incbuffett Warren ..., R. Ted Weschler,, and Kent J Thiry.On average, DaVita Inc executives and independent directors trade stock every 12 days with the average trade being worth of $11,404,005. The most recent stock trade was executed by Barbara J Desoer on 10 May 2024, trading 5,030 units of DVA stock currently worth $698,214.

What does DaVita Inc do?

about davita kidney care davita kidney care is a division of davita healthcare partners inc., a fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the united states and abroad. a leading provider of dialysis services in the united states, davita kidney care treats patients with chronic kidney failure and end stage renal disease. davita kidney care strives to improve patients' quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. as of march 31, 2015, davita kidney care operated or provided administrative services at 2,197 outpatient dialysis centers located in the united states serving approximately 174,000 patients. the company also operated 93 outpatient dialysis centers located in 10 countries outside the united states. davita kidney care supports numerous programs dedicated to creating positive,

What does DaVita Inc's logo look like?

DaVita Inc executives and stock owners

DaVita Inc executives and other stock owners filed with the SEC include:

• JavierRodriguez,
  Chief Executive Officer, Director
• JoelAckerman,
  Chief Financial Officer, Treasurer
• CharlesBerg,
  Director
• KathleenWaters,
  Chief Legal Officer
• Javier J. Rodriguez,
  CEO & Exec. Director
• LeAnneZumwalt,
  Group Vice President, Government Affairs
• Michael David Staffieri,
  Chief Operating Officer of Kidney Care
• Joel Ackerman,
  CFO & Treasurer
• Kathleen Alyce Waters,
  Chief Legal and Public Affairs Officer
• James O. Hearty,
  Chief Compliance Officer
• BarbaraDesoer,
  Independent Director
• PascalDesroches,
  Independent Director
• PamelaArway,
  Independent Chairman of the Board
• JohnNehra,
  Independent Director
• PaulDiaz,
  Independent Director
• PhyllisYale,
  Independent Director
• JimGustafson,
  Vice President - Investor Relations
• PaulaPrice,
  Independent Director
• ShawnGuertin,
  Director
• KennyGardner,
  Chief People Officer - DaVita Kidney Care
• JamesHearty,
  Chief Compliance Officer
• JohnWinstel,
  Chief Accounting Officer
• Kenneth Gardner Smith,
  Chief People Officer
• Kenny Gardner,
  Chief People Officer
• Atul Mathur,
  Exec. VP of Global Operations
• Bill Myers,
  VP of Marketing & Communications
• John D. Winstel,
  Chief Accounting Officer
• Jeanine Marie Jiganti,
  Chief Compliance Officer
• Peter T Grauer,
  Director
• James K Hilger,
  Vice President and Controller
• William L Roper,
  Director
• Carol Anthony Davidson,
  Director
• Roger Valine,
  Director
• Joseph C Mello,
  Chief Operations Officer
• Allen Nissenson,
  Chief Medical Officer
• R. Ted Weschler,,
  
• Hathaway Incbuffett Warren ...,
  
• Robert J Margolis,
  Co-Chairman of the Board
• Laura Mildenberger,
  SVP & Chief People Officer
• Kim M Rivera,
  VP, Gen. Counsel & Secretary
• Dennis Kogod,
  President - West
• Garry E Menzel,
  Senior Vice President, Finance
• David T Shapiro,
  Chief Compliance Officer
• Charles J Mcallister,
  Chief Medical Officer
• Steven J Udicious,
  V.P., Sec. and Gen. Counsel
• Joseph Schohl,
  VP, Secretary & Gen. Counsel
• Willard Woodson Jr Brittain,
  Director
• Nancy Ann Deparle,
  Director
• Mary Kowenhoven,
  Vice President - Strategy
• Thomas O Usilton,
  Group Vice President
• Patricia Jones,
  Chief People Officer
• C Raymond Jr Larkin,
  Director
• Christopher J Riopelle,
  Chief Compliance Officer
• Thomas L Kelly,
  Executive Vice President
• Luis Borgen,
  Chief Financial Officer
• Georgina Randolph,
  Senior Vice President
• Richard B Fontaine,
  Director
• Mark G Harrison,
  Chief Financial Officer
• Richard K Whitney,
  Chief Financial Officer
• Richard C Vaughan,
  Director
• Gary Beil,
  Vice President and Controller
• Patrick A Broderick,
  VP, Secretary & Gen. Counsel
• Lori Richardson Pelliccioni,
  Cheif Compliance Officer
• Michele J Hooper,
  Director
• Michael David Staffieri,
  Chief Operating Officer, DKC
• Kent J Thiry,
  Executive Chairman
• Gregory J. Moore,
  Director
• Jason M. Hollar,
  Director
• Adam H Schechter,
  Director
• Christopher Michael Berry,
  Chief Accounting Officer
• Wendy Lee Schoppert,
  Director